SORC-13 is under clinical development by Soricimed Biopharma and currently in Phase I for Prostate Cancer. According to GlobalData, Phase I drugs for Prostate Cancer have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SORC-13’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

SORC-13 overview

SORC-13 is under development for treatment of advanced refractory solid tumors such as epithelial ovarian cancer, colon cancer, non-small cell lung cancer, breast cancer, peritoneal cancer, esophageal cancer, uterine cancer, gastrointestinal stromal tumor, prostate cancer, parotid cancer, head and neck cancer, nasopharyngeal cancer, adenoid cystic cancer and pancreatic ductal adenocarcinoma and also for Coronavirus Disease 2019 (COVID-19). The drug candidate is administered as an intravenous infusion. It comprises of a bi-functional parent peptide called soricidin obtained from the shrew venom. The drug candidate targets TRPV6 ion channel.

Soricimed Biopharma overview

Soricimed Biopharma, formerly BioProspecting NB, is a pharmaceutical company. Its novel peptide target platform includes peptide receptor radionuclide therapy, peptide-drug conjugate program, SOR-C13 TRPV6 inhibitor and others. The company offers services such as the development and commercialization of therapeutic and diagnostic programs. Soricimed Biopharma’s products are used in the treatment of breast cancer, ovarian cancer, and prostate cancer, and other cancer types. It operates through a network of contract research organizations that provide research outside its core capacities. Soricimed Biopharma is headquartered in Moncton, New Brunswick, Canada.

For a complete picture of SORC-13’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.